专题:Cancer Mechanisms and Therapy

This cluster of papers focuses on the role of Pim oncogenes, particularly Pim-1 and Pim-2 kinases, in promoting tumorigenesis, cancer progression, and metastasis. The cluster also explores the potential of targeting Pim kinases as a therapeutic approach, with a specific emphasis on their involvement in cell survival pathways, phosphorylation of key proteins, and their association with hematological malignancies.
最新文献
Echinacoside as a Novel Ferroptosis Inducer in Hepatocellular Carcinoma: Mechanistic Insights from TP53/SLC7A11/GPX4 Pathway Modulation

article Full Text OpenAlex

C/EBPβ-induced alternative splicing of RCAN1 generates a potent TCR-T target in mesenchymal glioblastoma

article Full Text OpenAlex

Correction: Targeting ferroptosis: novel therapeutic approaches and intervention strategies for kidney diseases

article Full Text OpenAlex

Copper homeostasis and its dysregulation in diseases: A focus on cuproptosis

review Full Text OpenAlex

Transarterial chemoembolization with rivoceranib and camrelizumab for BCLC stage C hepatocellular carcinoma

article Full Text OpenAlex

Natural compounds naringin and nobiletin synergistically inhibit the PI3K/AKT/mTOR pathway in NSCLC: molecular docking and cytotoxicity studies

article Full Text OpenAlex

Circular RNA uridine-cytidine kinase (UCK) 2 ameliorates mitochondrial injury after cerebral ischemia reperfusion and promotes angiogenesis via modulating the microRNA-188-5p/phosphatase and tensin homolog axis.

article Full Text OpenAlex

Phytochemical Triad in Lung Cancer: Synergistic Mechanisms and Clinical Translation of Genistein, Piperine, and Resveratrol

article Full Text OpenAlex

Dinaciclib improves treatment response in chemoresistant hepatoblastoma

article Full Text OpenAlex

LINC02878/ZNF282/PYCR2 axis promotes proline synthesis and tumor progression in colorectal cancer

article Full Text OpenAlex

近5年高被引文献
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

review Full Text OpenAlex 1697 FWCI265.4519

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

article Full Text OpenAlex 1318 FWCI171.3185

Angiogenic signaling pathways and anti-angiogenic therapy for cancer

review Full Text OpenAlex 1072 FWCI167.4894

The role of BCL-2 family proteins in regulating apoptosis and cancer therapy

review Full Text OpenAlex 821 FWCI64.8845

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

article Full Text OpenAlex 795 FWCI116.123

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

article Full Text OpenAlex 675 FWCI105.1496

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

article Full Text OpenAlex 600 FWCI124.6599

Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer

review Full Text OpenAlex 534 FWCI124.0812

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

article Full Text OpenAlex 501 FWCI104.6341

The current state of the art and future trends in RAS-targeted cancer therapies

review Full Text OpenAlex 491 FWCI49.0759